arrow
G

Giuseppe Tonini

university campus bio-medico
H指数:85
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemotherapy Backbone and Outcomes of Immune Checkpoint Inhibitor Combinations Across Solid Tumors: A Pan-Tumor Network Meta-Analysis

化疗基础方案与免疫检查点抑制剂联合疗法在实体瘤中的疗效:一项泛肿瘤网络Meta分析

2026-09-170
OAAI
Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance

人工智能在骨转移中的应用:诊断和预后效能的系统评价与Meta分析

2026-08-300
OA
Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: An exploratory imaging-based analysis

骨转移负荷作为接受化疗-免疫治疗晚期非小细胞肺癌生存的强预后因素:一项基于影像学的探索性分析

2026-08-010
OAAI
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Breast CancerTrastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of combart prospective cohort study

乳腺癌:曲妥珠单抗-德鲁克特肯与放射治疗:COMBART前瞻性队列研究的 safety 子分析

2025-09-010
OAAI
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study☆

度伐鲁单抗在不可切除的III期非小细胞肺癌且不符合化疗指征的患者放疗后的应用:DUART II期非随机对照研究☆

2025-08-200
PREAI
THE ITALIAN MAURIS PHASE IIIB TRIAL OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH NEWLY DIAGNOSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER: 3-YEAR END-OF-STUDY RESULTS

意大利MAURIS 3期B研究:阿替利珠单抗联合卡铂和依托泊苷治疗新诊断广泛期小细胞肺癌的3年研究结束结果

2025-07-090
OAAI
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort

阿柏西普为基础和贝伐珠单抗为基础的二线方案在转移性结直肠癌患者中的应用:一项多中心队列研究的倾向性评分加权分析

2025-01-020
OAAI
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial

循环肿瘤DNA (ctDNA) 动态和治疗效果:来自II期DUART试验中不可切除III期NSCLC化疗不适宜患者(pts)的数据

2024-09-012
PRE
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models
2024-08-280
OAAI
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only (LL), right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials

FOLFOXIRI/贝伐单抗 (bev) 与双药/bev作为不可切除的肝脏 (LL),右侧和/或RAS或BRAF突变 (mut) 转移性结直肠癌 (mCRC) 的初始治疗: 基于个体患者数据的随机试验汇总分析

2024-06-010
PRE